Passer au contenu

/ Research

Je donne

Rechercher

Health Sciences; Medical Sciences

Marc Prentki

Professeur titulaire

Faculté de médecine - Département de nutrition

marc.prentki@umontreal.ca

Professeur accrédité

Faculté de médecine - Département de biochimie et médecine moléculaire

marc.prentki@umontreal.ca

Secondary numbers: 514 412-7648 (Télécopieur) 514 890-8000 #23642 (Travail 1)

Media

Portrait de chercheur : Dr Marc Prentki

 - © Université de Montréal

Profile

Research expertise

Signal transduction in the pancreatic β cell and regulation of insulin secretion. Glucose metabolism in the β cell triggers insulin secretion. The metabolic pathways involved in glucose-stimulated insulin secretion are still misunderstood. Our laboratory is working on the identification of the metabolic factors involved in coupling glucose metabolism and insulin secretion. We hypothesized that three metabolic cycles play a role in glucose-, fatty acid- and amino-acid-stimulated insulin secretion: the Krebs cycle, the pyruvate cycle and the glycerolipids/fatty acids cycle. With the help of a biochemical approach and molecular biology techniques such as the RNAi technology, adenovirus and KO mice, we are currently testing this hypothesis by overexpression or downregulation of key enzymes involved in intermediate metabolism regulation. We are also interested in the identification of genetic or nutritional defects (ex. excess of fatty acids) responsible for the aberrant insulin secretion in type 2 diabetes.

Etiology of Type 2 DiabetesType 2 diabetes is caused by a progressive dysfunction of the pancreatic β cell concomitant with insulin resistance of peripheral tissues. To better understand the molecular mechanism underlying this dysfunction and leading to the apoptosis of the b cells, our laboratory makes use of various animal models and primary (isolated islets of Langherans) or immortalized cell lines. The focus of our study are in vitro and in vivo glucolipotoxicity and the detoxification processes of fuel surfeit.Nutrition and cancerEpidemiological studies have underlined a link between the incidence of obesity and intestinal, breast and prostate cancers. Animal studies have also shown that a low calorie and low fat diet can reduce the risk of developping cancer. Nevertheless, the molecular mechanism by which fat induces cancer is still unknown. Our laboratory is testing the hypothesis by which the link between high-fat diet, obesity and cancer would reside in the glycerolipid/fatty acid cycle and the signalling through GPR40.

education

  • 1986 — Postdoctorat — BiochimieUniversité de Pennsylvanie
  • 1984 — Postdoctorat — BiochimieUniversité de Genève
  • 1974 — Baccalauréat — BiochimieUniversité de Genève
  • 1976 — Maîtrise — BiochimieUniversité de Genève
  • 1980 — Doctorat — BiochimieUniversité de Genève

Affiliations and responsabilities

Research affiliations

Research units

Membre

  • Centre de recherche du diabète de Montréal

Teaching and supervision

Student supervision

Theses and dissertation supervision (Papyrus Institutional Repository)

2021

α/β-hydrolase domain-6 and the development of high-fat diet-induced adipose tissue inflammation

Graduate : Schmitt, Clémence
Cycle : Master's
Grade : M. Sc.
2011

Monoacylglycerol as a metabolic coupling factor in glucose-stimulated insulin secretion

Graduate : Zhao, Shangang
Cycle : Master's
Grade : M. Sc.
2007

Fatty acid metabolism and modulation of human breast cancer cell survival

Graduate : Przybytkowski, Ewa
Cycle : Doctoral
Grade : Ph. D.
2003

Glucolipotoxicity and the control of pancreatic ℓ-cell apoptosis

Graduate : El-Assaad, Wisal
Cycle : Master's
Grade : M. Sc.

Projects

Research projects

2015 - 2024

Lipid metabolism, insulin secretion and energy homoestasis

Lead researcher : Marc Prentki
Funding sources: IRSC/Instituts de recherche en santé du Canada
Grant programs: PVXXXXXX-(FDN) Subvention Fondation
2018 - 2023

LINKING BASIC, CLINICAL & POPULATION HEALTH RESEARCH TO PREVENT & TREAT DIABETES, METABOLIC SYNDROME

Lead researcher : Pierre Haddad
Co-researchers : Marc Prentki
Funding sources: FCI/Fondation canadienne pour l'innovation
Grant programs: PVXXXXXX-Fonds d'exploitation des infrastructures (FEI)
2020 - 2021

Efficacy and mechanism of action of CB1R inverse agonists for enhancing insulin secretion and for preventing metabolic stress and cytokine-induced βcell death in human islets

Funding sources: MITACS Inc.
Grant programs: PVXXXXXX-Stage Accélération Québec - MITACS
2019 - 2020

ABHD6 as a novel drug target for obesity, non-alcoholic fatty liver disease (NASH) and cardiovascular disease (CVD)

Lead researcher : Marc Prentki
Funding sources: MITACS Inc.
Grant programs: PVXXXXXX-Stage Élévation Québec - MITACS
2019 - 2020

Efficacy of CB1R inverse agonists for enhancing insulin secretion in mouse and human islets, ex vivo, and for preventing cytokine-induced -cell death in human islets

Lead researcher : Marc Prentki
Funding sources: MITACS Inc.
Grant programs: PVXXXXXX-Stage Accélération Québec - MITACS
2012 - 2019

DIABETES AND METABOLISM

Lead researcher : Marc Prentki
Funding sources: SPIIE/Secrétariat des programmes interorganismes à l’intention des établissements
Grant programs: PVX50399-Chaires de recherche du Canada
2017 - 2018

CMDO - Réseau de recherche en santé cardiométabolique, diabète et obésité

Co-researchers : Marc Prentki
Funding sources: FRQS/Fonds de recherche du Québec - Santé (FRSQ)
Grant programs: PVXXXXXX-Réseaux thématiques de recherche
2013 - 2016

METABOLIC DECELARATION AS A MECHANISM FOR THE ANTI-DIABETIC EFFECTS OF METFORMIN AND BERBERINE

Lead researcher : Marc Prentki
Co-researchers : Guang Ning
Funding sources: IRSC/Instituts de recherche en santé du Canada
Grant programs: PVXXXXXX-(CCI) Initiative de recherche en santé conjointe Chine-Canada
2011 - 2016

GLUCOSE REGULATION OF INSULIN SECRETION AND METABOLIC ENZYMES'GENE EXPRESSION

Lead researcher : Marc Prentki
Funding sources: IRSC/Instituts de recherche en santé du Canada
Grant programs: PVXX5647-(MOP) Subvention de fonctionnement incluant les subventions de fonctionnement programmatiques (général)
2010 - 2016

MOLECULAR BASIS OF FUEL SURFEIT DETOXIFICATION IN PANCREATIC BETA-CELLS

Lead researcher : Marc Prentki
Funding sources: IRSC/Instituts de recherche en santé du Canada
Grant programs: PVXX5647-(MOP) Subvention de fonctionnement incluant les subventions de fonctionnement programmatiques (général)
2012 - 2015

THE MONTREAL CARDIOMETABOLIC BIOMARKER AND DRUG DISCOVERY CONSORTIUM (BIOCMET)

Lead researcher : Marc Prentki
Funding sources: Regroupement de compagnies, corporations canadiennes
Grant programs:
2012 - 2015

THE MONTREALCARDIOMETABOLIC BIOMARKER AND DRUG DISCOVERY CONSORTIUM (BIOCMET)

Lead researcher : Marc Prentki
Funding sources: MELS/Ministère de l'Éducation, du Loisir et du Sport
Grant programs:
2012 - 2015

THE MONTREAL CARDIOMETABOLIC BIOMARKER AND DRUG DISCOVERY CONSORTIUM (BIOCMET)

Lead researcher : Marc Prentki
Funding sources: FCI/Fondation canadienne pour l'innovation
Grant programs:
2009 - 2015

LINKING BASIC, CLINICAL AND POPULATION HEALTH RESEARCH TO PREVENT AND TREAT DIABETES, METABOLIC SYNDROME AND COMPLICATIONS

Lead researcher : Marc Prentki
Funding sources: FCI/Fondation canadienne pour l'innovation
Grant programs:
2009 - 2015

LINKING BASIC, CLINICAL AND POPULATION HEALTH RESEARCH TO PREVENT AND TREAT DIABETES, METABOLIC SYNDROME AND COMPLICATIONS

Lead researcher : Marc Prentki
Funding sources: IRCM/Institut de recherches cliniques de Montréal
Grant programs:
2009 - 2015

LINKING BASIC, CLINICAL AND POPULATION HEALTH RESEARCH TO PREVENT AND TREAT DIABETES, METABOLIC SYNDROME AND COMPLICATIONS

Lead researcher : Marc Prentki
Funding sources: Regroupement de compagnies, corporations canadiennes
Grant programs:
2009 - 2015

LINKING BASIC, CLINICAL AND POPULATION HEALTH RESEARCH TO PREVENT AND TREAT DIABETES, METABOLIC SYNDROME AND COMPLICATIONS

Lead researcher : Marc Prentki
Funding sources: Regroupement de compagnies, corporations canadiennes
Grant programs:
2009 - 2015

LINKING BASIC, CLINICAL AND POPULATION HEALTH RESEARCH TO PREVENT AND TREAT DIABETES, METABOLIC SYNDROME AND COMPLICATIONS

Lead researcher : Marc Prentki
Funding sources: MSSS/Ministère de la Santé et des Services sociaux
Grant programs:
2009 - 2015

LINKING BASIC, CLINICAL AND POPULATION HEALTH RESEARCH TO PREVENT AND TREAT DIABETES, METABOLIC SYNDROME AND COMPLICATIONS

Lead researcher : Marc Prentki
Funding sources: Regroupement de compagnies, corporations canadiennes
Grant programs:
2009 - 2015

LINKING BASIC, CLINICAL AND POPULATION HEALTH RESEARCH TO PREVENT AND TREAT DIABETES, METABOLIC SYNDROME AND COMPLICATIONS

Lead researcher : Marc Prentki
Funding sources: MSSS/Ministère de la Santé et des Services sociaux
Grant programs:
2013 - 2014

RECHERCHE FONDAMENTALE ET APPLIQUEE SUR LA PREVENTION DU DIABETE DE TYPE 2

Lead researcher : Marc Prentki
Funding sources: Financière Sun Life Canada
Grant programs:
2012 - 2014

SYMPOSIUM ON CARDIOMETABOLIC DISEASES OF THE MONTREAL DIABETES RESEARCH CENTER

Funding sources: IRSC/Instituts de recherche en santé du Canada
Grant programs: PV149034-Subventions pour planification

Outreach

Highlights

Hommage

2014

Portrait de chercheur

Découvrez le parcours professionnel de Marc Prentki, professeur à la Faculté de médecine de l’Université de Montréal.

For more information…

Publications and presentations

Publications

  • Sladek,R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., Boutin, P., Vincent, D., Belisle, A., Hadjadj, S., Balkau, B., Heude, B., Charpentier, G., Hudson, TJ., Montpetit, A., Prentki, M., Posner, BI., Balding, DJ., Meyre, D., Polychronakos, C., and Froguel. P. A Genome-wide association study identifies novel susceptibility loci for Type 2 Diabetes mellitus. Nature 2007; 445:881-885.
  • Peyot ML, Guay C, Latour MG, Lamontagne J, Lussier R, Pineda M, Ruderman NB, Haemmerle G, Zechner R, Joly E, Madiraju SR, Poitout V, Prentki M. Adipose Triglyceride Lipase Is Implicated in Fuel- and Non-fuel-stimulated Insulin Secretion. J Biol Chem 2009; 284:16848-59.
  • Peyot ML, Pepin E, Lamontagne J, Latour MG, Zarrouki B, Lussier R, Pineda M, Jetton TL, Madiraju SR, Joly E. Prentki M. Beta-cell failure in diet-induced obese mice stratified according to body weight gain: secretory dysfunction and altered islet lipid metabolism without steatosis or reduced beta-cell mass. Diabetes 2010; 59:2178-87.
  • Nolan, CJ, Damn, P. and Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011; 378:169-81.
  • Prentki M, Matschinsky FM, Madiraju SR. Metabolic signaling in fuel-induced insulin secretion. Cell Metab 2013; 18:162-185.
  • Lamontagne J, Jalbert-Arsenault E, Pepin E, Peyot ML, Ruderman NB, Nolan CJ, Joly E, Madiraju SR, Poitout V, Prentki M. Pioglitazone acutely reduces energy metabolism and insulin secretion in rats. Diabetes 2013; 62:2122-2129.
  • Zhao S, Mugabo Y, Iglesias J, Xie L, Delghingaro-Augusto V, Lussier R, Peyot M-L, Joly E, Davis MA, Brown JM, Abousalham A, Gaisano H, Madiraju SRM and Prentki M. ABHD6 accessible monoacylglycerol is a signal for glucose-stimulated insulin secretion. Cell Metab 2014;19:993-1007.
  • Nolan, CJ, Ruderman, NB, Kahn, SE, Pedersen, O, Prentki M. Insulin resistance as a physiological defense against metabolic stress: implication for the management of subsets of type 2 diabetes. Diabetes 2015; 64: 673-86.
  • Mugabo Y, Zhao S, Seifried A, Gezzar S, Al-Mass A, Zhang D, Lamontagne J, Attane C, Poursharifi P, Iglesias J, Joly E, Peyot ML, Gohla A, Madiraju SRM, and Prentki M. Identification of a mammalian glycerol-3-phosphate phosphatase: Role in metabolism and signaling in pancreatic β–cells and hepatocytes. Proc Natl Acad Sci USA 2016; 113:E430-E439.
  • Zhao S, Mugabo Y, Ballentyne G, Attane C, Iglesias J, Poursharifi P, Zhang D, Nguyen TA, Erb H, Prentki R, Peyot ML, Joly E, Tobin S, Fulton S, Brown JM, Madiraju SRM, and Prentki M. α/β- Hydrolase domain-6 deletion induces adipose browning and prevents obesity and type-2 diabetes. Cell Reports 2016 In Press.

Disciplines

  • Nutrition
  • Biochemistry
  • Medical Biochemistry
  • Molecular Biology
  • Molecular Medicine
  • Cell Biology

Areas of expertise

  • Nutrition
  • Nutritional Disorders
  • Obesity
  • Pancreas
  • Diabetes
  • Metabolic Disorders
  • Metabolic Diseases
  • Metabolism
  • Drug Metabolism
  • Energy Metabolism
  • Cell
  • Enzymes and Proteins
  • Glands and Tissues
  • Glucotoxicity
  • Nutrients
  • Drug Administration and Drug Interactions